A tool for converting Xbox 360 shaders to HLSL. Contribute to SnakeyFlea/06Recomp development by creating an account on GitHub.

Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

While the treatment was safe and well tolerated, the lack of biomarker improvement means that Vertex “will not be advancing [VX-264] further in clinical trials.” “Vertex plans to conduct ...

Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

Becoming a meal for a hungry flea probably isn’t on your to-do list ... of your home to identify impacted areas and take steps to control all life stages of the pest. They’ll also provide ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation ... the new drug approvals for CF treatment Alyftrek and non-opioid pain reliever Journavx.

Vertex will not advance VX-264 trials after the study failed to meet efficacy endpoints, despite being generally safe and well tolerated. Zimislecel, Vertex’s islet cell therapy, remains on ...

The past year has been transformative for Vertex, marked by the launch of Casgevy, a groundbreaking treatment for sickle cell disease patients. This one-time, gene-edited cell therapy, developed ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...